Abstract:Chimeric antigen receptor (CAR)-modified T cells brought a paradigm shift in the treatment of chemotherapy-resistant lymphomas. Conversely, clinical experience with CAR T cells targeting solid tumors has been disheartening, indicating the necessity of their molecular-level optimization. While incorporating CD28 or 41BB costimulatory domains into CARs in addition to the CD3z signaling domain improved the long-term efficacy of T cell products, their influence on early tumor engagement has yet to be elucidated. We studied the antigen-independent self-association and membrane diffusion kinetics of first- (.z), second- (CD28.z, 41BB.z), and third- (CD28.41BB.z) generation HER2-specific CARs in the resting T cell membrane using super-resolution AiryScan microscopy and fluorescence correlation spectroscopy, in correlation with RoseTTAFold-based structure prediction and assessment of oligomerization in native Western blot. While .z and CD28.z CARs formed large, high-density submicron clusters of dimers, 41BB-containing CARs formed higher oligomers that assembled into smaller but more numerous membrane clusters. The first-, second-, and third-generation CARs showed progressively increasing lateral diffusion as the distance of their CD3z domain from the membrane plane increased. Confocal microscopy analysis of immunological synapses showed that both small but highly mobile CD28.41BB.z and large but less mobile .z CAR clusters induced more efficient CD3ζ and pLck phosphorylation than CD28.z or 41BB.z CARs organized in clusters of intermediate size and mobility. However, electric cell-substrate impedance sensing revealed that the CD28.41BB.z CAR performs worst in sequential short-term elimination of adherent tumor cells, while the .z CAR is superior to all others. We conclude that the molecular structure, membrane organization, and mobility of CARs are critical design parameters that can predict the development of an effective immune synapse. Therefore, they need to be taken into account alongside the long-term biological effects of costimulatory domains to achieve an optimal therapeutic effect.

Incorporation Of 4-1bb Endowed The Potent Cd33 Specific Chimeric Antigen Receptor T Cells With Anti-Exhaustion Capacity And Increased Central Memory Compartment

CD33 specific chimeric antigen receptor T cells with different costimulators showed potent anti-leukemia efficacy and different phenotype.

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Arming CAR-T Cells with Cytokines and More: Innovations in the Fourth-Generation CAR-T Development

Incorporation of Id3 enhances CAR T cell therapeutic efficacy against solid tumors in an immunocompetent murine model

Chimeric Antigen Receptor-T Cells With 4-1bb Co-Stimulatory Domain Present A Superior Treatment Outcome Than Those With Cd28 Domain Based On Bioinformatics

Combination of 4-1BB and DAP10 promotes proliferation and persistence of NKG2D(bbz) CAR-T cells

Chimeric Antigen Receptors Containing the OX40 Signalling Domain Enhance the Persistence of T Cells Even under Repeated Stimulation with Multiple Myeloma Target Cells

Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells

Combined 4-1BB and ICOS co-stimulation improves anti-tumor efficacy and persistence of dual anti-CD19/CD20 chimeric antigen receptor T cells

C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies

Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

Developing a membrane-proximal CD33-targeting CAR T cell

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency